Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 17/20 | 0.71 |
| ▸ | PGR | P06401 | 4/20 | 0.71 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.63 |
| ▸ | AR | P10275 | 2/20 | 0.63 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.37 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6933669 | 1.00 | NR3C1 (0.71) | NR3C1PGRNR3C2ARAKR1B1 | |
| SCHEMBL3963221 | 0.93 | NR3C1 (0.72) | NR3C1PGRNR3C2AR | |
| SCHEMBL7181872 | 0.93 | NR3C1 (0.72) | NR3C1PGRNR3C2ARAKR1B1 | |
| SCHEMBL7181866 | 0.93 | NR3C1 (0.72) | NR3C1PGRNR3C2ARAKR1B1 | |
| SCHEMBL3963218 | 0.93 | NR3C1 (0.72) | NR3C1PGRNR3C2AR | |
| SCHEMBL7183118 | 0.92 | NR3C1 (0.60) | NR3C1PGRNR3C2AR | |
| SCHEMBL7183124 | 0.92 | NR3C1 (0.60) | NR3C1PGRNR3C2AR | |
| SCHEMBL3969492 | 0.90 | NR3C1 (0.59) | NR3C1PGRNR3C2AR | |
| SCHEMBL3969499 | 0.90 | NR3C1 (0.59) | NR3C1PGRNR3C2AR | |
| SCHEMBL3959842 | 0.90 | NR3C1 (0.58) | NR3C1PGRNR3C2ARTAS2R14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363876-A1 | GLUCOCORTICOID RECEPTOR MODULATORS | Abbott Laboratories (US) | 2003-11-26 | — | — | EP | disclosed |
| US-6583180-B2 | Antidiabetic agents | ABBOTT LABORATORIES | 2003-06-24 | — | — | US | disclosed |
| US-20020156311-A1 | Glucocorticoid receptor modulators | KARO BIO AB (SE) | 2002-10-24 | — | — | US | disclosed |
| WO-2002064550-A1 | GLUCOCORTICOID RECEPTOR MODULATORS | ABBOTT LABORATORIES (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156311-A1 | Glucocorticoid receptor modulators | NR3C1, NR5A1, NR3C2 | NR3C1 1/4885PGR 249/4885NR3C2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.